{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:8236"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:8236","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Studies of novel risk factors associated with chronic kidney disease in ethically diverse, high risk populations","abstract":"Chronic Kidney Disease (CKD) is common and often has a major impact on the health of those affected. In this thesis I have focused on areas of uncertainty that may have major implications for patient care. Firstly, I assessed the determinants of increased mortality in a multi-ethnic primary care population. Secondly, I investigated the differential progression of CKD between ethnicities. Thirdly, I assessed if tryptase, as a marker of mast cell activation, could be used to stratify risk in CKD. Finally, I investigated the impact of CKD on health related quality of life (HRQL) and the association between HRQL and clinical end-points. I found that: (i) comorbidity has a profound impact at a population level on survival in CKD; (ii) albuminuria is the principle modifiable risk factor for progression to end-stage renal disease (ESRD) in people of South Asian ethnicity; (iii) serum tryptase is an independent prognostic factor for ESRD in patients with CKD receiving treatment with an ACEi or ARB; and (iv) Low HRQL is common in CKD and reduced HRQL is associated with a higher risk for death. The findings from this thesis contribute to the understanding of CKD in ethnically diverse, high-risk populations and form the basis for further studies.","abstract_html":"Chronic Kidney Disease (CKD) is common and often has a major impact on the health of those affected. In this thesis I have focused on areas of uncertainty that may have major implications for patient care. Firstly, I assessed the determinants of increased mortality in a multi-ethnic primary care population. Secondly, I investigated the differential progression of CKD between ethnicities. Thirdly, I assessed if tryptase, as a marker of mast cell activation, could be used to stratify risk in CKD. Finally, I investigated the impact of CKD on health related quality of life (HRQL) and the association between HRQL and clinical end-points. I found that: (i) comorbidity has a profound impact at a population level on survival in CKD; (ii) albuminuria is the principle modifiable risk factor for progression to end-stage renal disease (ESRD) in people of South Asian ethnicity; (iii) serum tryptase is an independent prognostic factor for ESRD in patients with CKD receiving treatment with an ACEi or ARB; and (iv) Low HRQL is common in CKD and reduced HRQL is associated with a higher risk for death. The findings from this thesis contribute to the understanding of CKD in ethnically diverse, high-risk populations and form the basis for further studies.","abstract_has_math":false,"creators":["Jesky, Mark David"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2018,"date_issued":"2018-07","date_published":"2018-07","updated_at":"2026-11-19T09:30:07Z","subjects":["R Medicine (General)"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/8236/2/Jesky18PhD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A8236","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["other"]},{"key":"dc:creator","label":"Author","values":["Jesky, Mark David"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2018-07"]},{"key":"dc:date.issued","label":"Date","values":["2018-07"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/8236/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["R Medicine (General)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/8236/2/Jesky18PhD.pdf","http://etheses.bham.ac.uk//id/eprint/8236/1/Decl_IS_Jesky18PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Chronic Kidney Disease (CKD) is common and often has a major impact on the health of those affected. In this thesis I have focused on areas of uncertainty that may have major implications for patient care. Firstly, I assessed the determinants of increased mortality in a multi-ethnic primary care population. Secondly, I investigated the differential progression of CKD between ethnicities. Thirdly, I assessed if tryptase, as a marker of mast cell activation, could be used to stratify risk in CKD. Finally, I investigated the impact of CKD on health related quality of life (HRQL) and the association between HRQL and clinical end-points. I found that: (i) comorbidity has a profound impact at a population level on survival in CKD; (ii) albuminuria is the principle modifiable risk factor for progression to end-stage renal disease (ESRD) in people of South Asian ethnicity; (iii) serum tryptase is an independent prognostic factor for ESRD in patients with CKD receiving treatment with an ACEi or ARB; and (iv) Low HRQL is common in CKD and reduced HRQL is associated with a higher risk for death. The findings from this thesis contribute to the understanding of CKD in ethnically diverse, high-risk populations and form the basis for further studies."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public","staffonly"]},{"key":"dc:title","label":"Title","values":["Studies of novel risk factors associated with chronic kidney disease in ethically diverse, high risk populations"]}]}],"canonical_facts":{"dc:contributor.sponsor":["other"],"dc:creator":["Jesky, Mark David"],"dc:date":["2018-07"],"dc:date.issued":["2018-07"],"dc:description.abstract":["Chronic Kidney Disease (CKD) is common and often has a major impact on the health of those affected. In this thesis I have focused on areas of uncertainty that may have major implications for patient care. Firstly, I assessed the determinants of increased mortality in a multi-ethnic primary care population. Secondly, I investigated the differential progression of CKD between ethnicities. Thirdly, I assessed if tryptase, as a marker of mast cell activation, could be used to stratify risk in CKD. Finally, I investigated the impact of CKD on health related quality of life (HRQL) and the association between HRQL and clinical end-points. I found that: (i) comorbidity has a profound impact at a population level on survival in CKD; (ii) albuminuria is the principle modifiable risk factor for progression to end-stage renal disease (ESRD) in people of South Asian ethnicity; (iii) serum tryptase is an independent prognostic factor for ESRD in patients with CKD receiving treatment with an ACEi or ARB; and (iv) Low HRQL is common in CKD and reduced HRQL is associated with a higher risk for death. The findings from this thesis contribute to the understanding of CKD in ethnically diverse, high-risk populations and form the basis for further studies."],"dc:format":["application/pdf"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/8236/2/Jesky18PhD.pdf","http://etheses.bham.ac.uk//id/eprint/8236/1/Decl_IS_Jesky18PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/8236/"],"dc:subject":["R Medicine (General)"],"dcterms:accessrights":["public","staffonly"],"dc:title":["Studies of novel risk factors associated with chronic kidney disease in ethically diverse, high risk populations"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"]},"updated_at":"2026-11-19T09:30:07Z"}